Physician profile
Shwetha Rupendu
NPI 1467004366
$2,846.70
in general payments reported to CMS, 2019-2025
23 companies · $13.87 in 2025
The $13.87 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $275 · 2021: $1,009 · 2022: $999 · 2023: $177 · 2024: $122 · 2025: $13.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $737.00 | 2019-2024 | Breztri |
| Janssen Pharmaceuticals, INC | $734.16 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $155.35 | 2019-2023 | Ultomiris |
| Novo Nordisk INC | $142.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $132.56 | 2021-2022 | |
| Gilead Sciences, INC. | $120.38 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $104.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.31 | 2022 | |
| Abbvie INC. | $98.23 | 2021-2024 | Teflaro, Dalvance |
| Boston Scientific Corporation | $97.40 | 2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.64 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $80.00 | 2022 | |
| Pfizer INC. | $45.51 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $29.42 | 2024-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $26.75 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.07 | 2019 | |
| Bioxcel Therapeutics, INC. | $21.90 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $21.00 | 2019 | |
| Teleflex LLC | $20.04 | 2024 | Arrow |
| Incyte Corporation | $17.95 | 2022 | |
| Karyopharm Therapeutics INC. | $17.06 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.68 | 2021 | |
| Glaxosmithkline, LLC. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shwetha Rupendu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.